Cite
MLA Citation
Heng Liang et al.. “IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.” Cancer letters, vol. 522, 2021, pp. 32–43. http://access.bl.uk/ark:/81055/vdc_100144243295.0x000037